Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DK210 (CD20)
- Development stage
- Preclinical
- Lead developer
- DEKA Biosciences
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
DK210 (CD20) is an engineered cytokine fusion protein developed by DEKA Biosciences using its proprietary Diakine™ platform. The molecule consists of a dual-cytokine payload—specifically interleukin-2 (IL-2) and interleukin-10 (IL-10)—fused to a targeting antibody fragment directed against the B-cell marker CD20. This 'Diakine' structure is designed to deliver potent immune-modulating signals directly to the tumor microenvironment of CD20-positive hematological malignancies, such as B-cell lymphomas and leukemias. By combining IL-2 (a pro-inflammatory T-cell activator) with IL-10 (which can have context-dependent anti-inflammatory or CD8+ T-cell stimulatory effects), the drug aims to maximize anti-tumor efficacy while minimizing systemic toxicity. The CD20-targeted version of DK210 is currently in early-stage development for various B-cell cancers.
- Other names
- CD20-targeted IL-2/IL-10 Diakine
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)IL10RA (Interleukin-10 Receptor)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on DK210 (CD20).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DK210 (CD20).